Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure

Yuya Matsue, Iziah E Sama, Douwe Postmus, Marco Metra, Barry H Greenberg, Gad Cotter, Beth A Davison, G Michael Felker, Gerasimos Filippatos, Peter Pang, Piotr Ponikowski, Thomas Severin, Claudio Gimpelewicz, Adriaan A Voors*, John R Teerlink

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Downloads (Pure)


OBJECTIVES: The aim of this study was to investigate the association between systolic blood pressure (SBP) drop, worsening renal function (WRF), and prognosis in patients with acute heart failure (AHF).

BACKGROUND: A large drop in SBP early after hospital admission for AHF might be associated with increased risk for WRF and prognosis. However, there is a paucity of data regarding the interaction between WRF and a drop in SBP on clinical outcomes.

METHODS: A post hoc analysis among 6,544 patients with AHF enrolled in the RELAX-AHF-2 (Relaxin in Acute Heart Failure-2) trial was performed. Blood pressure was uniformly and repetitively measured. Peak SBP drop was defined as the difference between baseline SBP and lowest SBP documented during the first 48 hours. WRF was defined by an increase in serum creatinine of ≥0.3 mg/dL from baseline to day 5.

RESULTS: Peak SBP drop was independently associated with a higher risk for WRF (HR: 1.11 per 10 mm Hg SBP drop; P < 0.001), 5-day worsening heart failure (HR: 1.12 per 10 mm Hg SBP drop; P = 0.006), and 180-day cardiovascular death (HR: 1.09 per 10 mm Hg SBP drop; P = 0.026) after adjustment for potential confounders including baseline SBP. There was no interaction between the prognostic value of early SBP drop according to the presence or absence of WRF.

CONCLUSIONS: In patients hospitalized for AHF, a greater early drop in SBP was associated with a higher incidence of WRF, worsening heart failure, and an increased risk for 180-day cardiovascular death. However, the association between SBP drop and prognosis was not influenced by WRF. (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778).

Original languageEnglish
Pages (from-to)890-903
Number of pages14
JournalJACC. Heart failure
Issue number12
Early online date6-Oct-2021
Publication statusPublished - Dec-2021

Cite this